Clinical Trials Seek to Improve Warriors’ Burn Care

FORT DETRICK, Md. — New hope is on the hori­zon for wound­ed war­riors suf­fer­ing debil­i­tat­ing burns as the Armed Forces Insti­tute of Regen­er­a­tive Med­i­cine and its part­ners at lead­ing med­ical research cen­ters launch three promis­ing clin­i­cal tri­als.
Burns are among the most painful and debil­i­tat­ing bat­tle­field wounds and often turn dead­ly if infec­tion sets in. In an effort to speed up the devel­op­ment of rev­o­lu­tion­ary new treat­ments for burns and oth­er com­mon bat­tle­field injuries, the Defense Depart­ment launched AFIRM in 2008.

Just three years into the pro­gram, AFIRM is see­ing big signs of suc­cess as it helps advance tech­nolo­gies that use lab­o­ra­to­ry-grown tis­sues and biosyn­thet­i­cal­ly devel­oped com­pounds to treat injuries and ill­ness­es. The ulti­mate aim of regen­er­a­tive med­i­cine is to enable patients’ bod­ies to re-grow bones, skin and tis­sues — even whole organs and limbs. Ten clin­i­cal tri­als already are under way or about to start in five areas spe­cif­ic to wound­ed war­rior care. Three focus on burn repair. 

The idea, explained AFIRM Direc­tor Ter­ry Irgens, is to push the enve­lope in explor­ing tech­nolo­gies that, while promis­ing, are sim­ply too expen­sive for the pri­vate sec­tor to pur­sue alone. 

With fund­ing from the Army Med­ical Research and Mate­r­i­al Com­mand, as well as the Navy, Air Force, Nation­al Insti­tutes of Health, Depart­ment of Vet­er­ans Affairs and oth­er pub­lic and pri­vate enti­ties, AFIRM is help­ing advance tech­nolo­gies over the gap referred to as the “val­ley of death.” 

“It’s where the exist­ing tech­nol­o­gy ends, and there is a gap and nobody has the fund­ing to get it to the next step,” Irgens said. 

Two research con­sor­tia, made up of some of the best and bright­est minds from 31 uni­ver­si­ties, are part­ner­ing with the U.S. Army Insti­tute for Sur­gi­cal Research at Fort Sam Hous­ton, Texas, to help bridge that gap. 

The goal is to get an indus­try part­ner to step in and pick up where they leave off, Irgens said. “Once you get some good, promis­ing data, that’s when the com­mer­cial com­pa­nies will come for­ward,” he said. 

One of the new clin­i­cal tri­als, now enter­ing its sec­ond phase, involves spray­ing a patient’s own healthy cells onto the burned area. 

Sev­en patients already are enrolled in the tri­al, with a quo­ta of 106 to par­tic­i­pate based on the Fed­er­al Drug Admin­is­tra­tion pro­to­col, Irgens said. As many as a dozen hos­pi­tals will be involved in the tri­al, with the Army Insti­tute for Sur­gi­cal Research expect­ed to join it this summer. 

Dr. Smi­ta Bhon­sale, AFIRM’s deputy direc­tor for sci­ence and tech­nol­o­gy, explained how the spray treat­ment works. The patient is rolled into the oper­at­ing room, where doc­tors har­vest a postage-stamp-size piece of skin from an unburned part of the body. The biop­sy is bro­ken apart into sin­gle cells, which are then sus­pend­ed in a gel-like solu­tion so they can mul­ti­ply and cre­ate new skin tis­sue. With­in a mat­ter of hours, the cells are sprayed onto the patient’s burns, cov­er­ing an area up to 80 times the size of the orig­i­nal biop­sy. The pro­ce­dure requires no skin grafts and, because the cells are grown from the patients’ own tis­sue, there’s no risk of rejection. 

Anoth­er clin­i­cal tri­al, also enter­ing its sec­ond phase, will use the patient’s own healthy skin cells and mul­ti­ply them in a flask under lab­o­ra­to­ry con­di­tions. But rather than spray­ing the new cells onto the patient, doc­tors will apply the new cells as sheets of skin. 

Up to 14 patients are expect­ed to par­tic­i­pate in that clin­i­cal tri­al, to be con­duct­ed at the Army Insti­tute for Sur­gi­cal Research. 

Unlike the spray tech­nol­o­gy that’s effec­tive only on more super­fi­cial burns, this process can be used to treat patients with more severe, third-degree burns, Bhon­sale explained. It elim­i­nates the need for exten­sive and repeat­ed skin graft­ing, and because it uses the patient’s own skin cells, the body won’t reject the new cells. 

While promis­ing, the tech­nol­o­gy isn’t with­out its draw­backs. The new skin takes up to six weeks to grow — requir­ing oth­er tem­po­rary dress­ing to pre­vent infec­tion and pro­tein loss. A third clin­i­cal tri­al, now enter­ing its sec­ond phase, will use a biosyn­thet­ic skin sub­sti­tute to treat deep, third-degree burns. Thir­ty patients are expect­ed to par­tic­i­pate at four pro­posed sites, includ­ing the Army Insti­tute for Sur­gi­cal Research. 

The advan­tage of biosyn­thet­ic skin is that it can be devel­oped in a lab­o­ra­to­ry set­ting and put into stor­age in a refrig­er­a­tor until it’s need­ed, explained Army Lt. Col. Bri­an Moore, AFIRM’s deputy director. 

“This is some­thing we are very inter­est­ed in because we can grow a lot of it and then put it on the shelf,” he said. “Then when some­one gets burned, we can take that off the shelf and apply it.” 

Because burn patients could receive this treat­ment imme­di­ate­ly, they have less risk of infec­tion and pro­tein loss. And, unlike skin from cadav­ers, which typ­i­cal­ly is used as a tem­po­rary wound cov­er­ing for burn patients, the biosyn­thet­ic skin con­tains sub­stances that help the body bet­ter accept future skin grafts, Moore explained. 

But there’s a down side to this treat­ment, too. Biosyn­thet­ic skin is a tem­po­rary fix, and at least for now, and must be removed lat­er and replaced with liv­ing cells. Also, the new cells have no pig­men­ta­tion or sweat glands, but Bhon­sale said sci­en­tists already are at work on the next-gen­er­a­tion tech­nol­o­gy to address the shortcoming. 

Although all of the clin­i­cal tri­als are being con­duct­ed inde­pen­dent­ly, Irgens said the syn­thet­ic skin, if it achieves FDA approval, could some­day allow burn patients to begin heal­ing until their own har­vest­ed cells are able to take over. 

As the clin­i­cal tri­als go on, AFIRM is explor­ing a broad range of oth­er prod­ucts and tech­nolo­gies to bet­ter treat burn patients. One is a spe­cial­ly designed “skin gun” that sprays a solu­tion of cells and water onto burn areas with­out injur­ing the cells. 

Anoth­er new device, called the Bio­Print­er, looks like a typ­i­cal ink-jet com­put­er print­er. But instead of dif­fer­ent-col­ored inks, its car­tridges are filled with skin cells grown from the patient’s own healthy cells. The print­er sprays them onto the wound to pro­mote a healthy recovery. 

AFIRM also is work­ing to devel­op bet­ter ban­dages to pro­mote burn heal­ing and burn treat­ments using mol­e­c­u­lar iodine, the spice cur­cum­in found in Indi­an cur­ries, and stem cells from amni­ot­ic flu­id, pla­cen­ta, bone mar­row and fat. 

Irgens empha­sized that tech­nolo­gies being advanced by AFIRM all have to go through a long FDA approval process and won’t be deliv­ered to the mar­ket­place for at least three to five years. “FDA is very par­tic­u­lar, and we want to make sure every­thing is safe,” he said. “That’s the first con­cern we all have. We do not want to harm any patients. We want to make them better.” 

But once the approvals come and the tech­nolo­gies advance to the main­stream, Irgens said he believes the work start­ed under the AFIRM pro­gram will have a far-reach­ing impact. “We feel this is very crit­i­cal ther­a­py. This is going to change the land­scape, once this gets approved,” he said. “It undoubt­ed­ly is going to move the lev­el of care up a notch.” That will have a huge impact on wound­ed war­riors suf­fer­ing from burns, Moore said. “The big thrust behind this is try­ing to restore peo­ple back to nor­mal­cy,” he said. “You will nev­er com­plete­ly restore that func­tion­al­i­ty they had pri­or to the injury. But at least you will allow them to have some kind of nor­mal­cy and func­tion­ing in their day-to-day activities.” 

The ben­e­fit will extend far beyond the mil­i­tary, Irgens said. “We are not devel­op­ing any­thing mil­i­tary-unique,” he said. “We are devel­op­ing tech­nol­o­gy that could sup­port mankind — both civil­ian and military.” 

Source:
U.S. Depart­ment of Defense
Office of the Assis­tant Sec­re­tary of Defense (Pub­lic Affairs) 

More news and arti­cles can be found on Face­book and Twitter.

Fol­low GlobalDefence.net on Face­book and/or on Twit­ter

Team GlobDef

Team GlobDef

Seit 2001 ist GlobalDefence.net im Internet unterwegs, um mit eigenen Analysen, interessanten Kooperationen und umfassenden Informationen für einen spannenden Überblick der Weltlage zu sorgen. GlobalDefenc.net war dabei die erste deutschsprachige Internetseite, die mit dem Schwerpunkt Sicherheitspolitik außerhalb von Hochschulen oder Instituten aufgetreten ist.

Alle Beiträge ansehen von Team GlobDef →